Drug intelligence / Profile preview

CTH-600

Development stage: Preclinical
Lead developer: Cartherics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CTH-600 is an investigational cell therapy classified as a CAR-NK (chimeric antigen receptor natural killer) product. It is being developed by Cartherics for the treatment of neoplasms, specifically solid tumors. The drug is currently in preclinical development and has not yet entered clinical trials or received regulatory approval. As a CAR-NK therapy, CTH-600 involves genetically engineered natural killer cells designed to target and destroy cancer cells expressing specific antigens associated with solid tumors. The precise target antigen and detailed mechanism of action have not been disclosed publicly[1].

Targets

TAG-72

Beyond the preview

Go deeper on CTH-600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTH-600.

Explore the full profile